JeanMarie Guenot is the President and CEO of Amphivena Therapeutics (http://amphivena.com/leadership/). She has her Ph. D. and has over 20 years under her belt in the pharmaceutical and biotechnology industry. She is featured within LinkedIn, the world’s largest professional network, with information dating as far back as 1987. JeanMarie has worked hard her whole life, creating her success and helping individuals to the best she can. She has worked within the public as well as private and has incredible knowledge in the areas of oncology, cardiovascular diseases, autoimmune diseases, neurology and ophthalmic diseases. After achieving her Ph. D. she began working as a principal scientist at a company called Roche.
According to Dr. Guenot’s website (http://jeanmarieguenot.com/) Roche is a global inventor in pharmaceuticals and diagnostics and the world’s largest company of biotechnology. After working there for six years, she then went on to achieve her Masters in Business Management while beginning a new job at another biotechnology company called Atlas Venture. JeanMarie Guenot choose a career path of strenuous intellect, long hours and huge results. She founded a company called SKS Ocular, a private ophthalmology company to discover and advance therapeutics, in 2009. The purpose of this company is to transform treatments for ocular diseases, diseases that cause problems to the eyes mainly concerning vision, in order to preserve or improve patients vision.
Today, as mentioned earlier, JeanMarie Guenot works for a company called Amphivena Therapeutics. It is a company that has a focus on blood cancers. There is a goal of using a new creation of therapy that harnesses a patients immune system to target and destroy tumor cells as well as particular compounds in connection with these tumor cells in order to prevent new ones. An individual would highly benefit if they needed to utilize a service JeanMarie and her company can provide. They can restore balance within an individual suffering from blood cancers. This balance is what is necessary for the proper function of blood circulation and function, as well s blood formation. Jeanmarie Guenot recently negotiated a partnership with Takeda, in which Amphivena will work with them to develop biotechnology.